RE:RE:RE:we would need 4 more people like lynne gagnonAureus, I mostly agree with your position, but not fully. I certainlt agree tht the focus should now be to results from clinical trials, FDA approval and commercialization (and partnering). But this should not be to the exclusion of research and dev. This must continue as they have a huge pipline that needs to be developed. It is not as though they need to search for new miracle drugs. they have a long line of proteins they need to pick from and move forward, and they have a long list of indications for 4050 to move forward as well - so there is a lot for Moran and Gagnon to do. Just the research end of the work, and more testing in mice etc., should not be the main focus at major analyst meetings and the quarterlies and AGM. The new research can suffice with a PR when they have smoething new (for now). The public focus now should be squarely on the business and commercialization and the underlting FDA decisions and approvals. But in private or away from the focus the management needs to keeps ALL the balls in the air at the same time.